CA2249348C - Preparation comprenant une combinaison de 5-methylisoxazol-4-acide carboxylique-(4-trifluoromethyl)-anilide et de n-(4-trifluoromethylphenyl)-2-cyano-3-acide hydroxycrotonique amide - Google Patents

Preparation comprenant une combinaison de 5-methylisoxazol-4-acide carboxylique-(4-trifluoromethyl)-anilide et de n-(4-trifluoromethylphenyl)-2-cyano-3-acide hydroxycrotonique amide Download PDF

Info

Publication number
CA2249348C
CA2249348C CA002249348A CA2249348A CA2249348C CA 2249348 C CA2249348 C CA 2249348C CA 002249348 A CA002249348 A CA 002249348A CA 2249348 A CA2249348 A CA 2249348A CA 2249348 C CA2249348 C CA 2249348C
Authority
CA
Canada
Prior art keywords
composition
component
compound
cancer
content
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002249348A
Other languages
English (en)
Other versions
CA2249348A1 (fr
Inventor
Robert Bartlett
Johann Then
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Sanofi Aventis Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19610955A external-priority patent/DE19610955A1/de
Application filed by Sanofi Aventis Deutschland GmbH filed Critical Sanofi Aventis Deutschland GmbH
Publication of CA2249348A1 publication Critical patent/CA2249348A1/fr
Application granted granted Critical
Publication of CA2249348C publication Critical patent/CA2249348C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002249348A 1996-03-20 1997-03-07 Preparation comprenant une combinaison de 5-methylisoxazol-4-acide carboxylique-(4-trifluoromethyl)-anilide et de n-(4-trifluoromethylphenyl)-2-cyano-3-acide hydroxycrotonique amide Expired - Lifetime CA2249348C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19610955.8 1996-03-20
DE19610955A DE19610955A1 (de) 1996-03-20 1996-03-20 Kombinationspräparat, enthaltend 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl)- anilid und N-(4-Trifluormethylphenyl)-2-cyan-3- hydroxycrotonsäureamid
PCT/EP1997/001167 WO1997034600A1 (fr) 1996-03-20 1997-03-07 Preparation comprenant une combinaison de 5-methylisoxazol-4-acide carboxylique-(4-trifluoromethyl)-anilide et de n-(4-trifluoromethylphenyl)-2-cyano-3-acide hydroxycrotonique amide

Publications (2)

Publication Number Publication Date
CA2249348A1 CA2249348A1 (fr) 1997-09-25
CA2249348C true CA2249348C (fr) 2006-10-03

Family

ID=37101799

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002249348A Expired - Lifetime CA2249348C (fr) 1996-03-20 1997-03-07 Preparation comprenant une combinaison de 5-methylisoxazol-4-acide carboxylique-(4-trifluoromethyl)-anilide et de n-(4-trifluoromethylphenyl)-2-cyano-3-acide hydroxycrotonique amide

Country Status (1)

Country Link
CA (1) CA2249348C (fr)

Also Published As

Publication number Publication date
CA2249348A1 (fr) 1997-09-25

Similar Documents

Publication Publication Date Title
AU705692B2 (en) Preparation containing a combination of 5-methylisoxazole-4 -carboxylic acid-(4-trifluoromethyl)-anilide and n-(4-trifluoromethylphenyl)2-cyano-3-hydroxycrotonic acid amide
EP0306060B1 (fr) Produits pharmaceutiques provoquant une analgésie accrue
DE202006020331U1 (de) Neue, pharmazeutische modifizierte Freisetzungs-Dosisform Cyclooxygenase-Enzym-Inhibitor
CA2249348C (fr) Preparation comprenant une combinaison de 5-methylisoxazol-4-acide carboxylique-(4-trifluoromethyl)-anilide et de n-(4-trifluoromethylphenyl)-2-cyano-3-acide hydroxycrotonique amide
IE62333B1 (en) Use of aromatic carboxylic acid amides
CN113677660A (zh) 乙酰水杨酸衍生物及其应用
EP1137438B1 (fr) Formulation a spectre therapeutique elargi, contenant des inhibiteurs de la synthese des nucleotides
KR20210042042A (ko) 페놀라민 g형 결정, 제조 방법과 그의 조성물 및 용도
JPH0140009B2 (fr)
JP3982889B2 (ja) イブプロフェン含有医薬製剤
CH667592A5 (de) 9,10-dihydrogenierte ergotalkaloide enthaltende pharmazeutische zusammensetzungen.
US3949082A (en) Thiadiazoles as anti-inflammatory agents
MXPA98007564A (en) Preparation in combination containing 5-methyl-4'-trifluometil-4'-isoxazolcarboxanilide and n- (4-trifluorometilfenil) -2-cyano-3-hydroxicrotonam
GB2163957A (en) Anti-asthma compositions containing ketotifen
JPS5921615A (ja) 鎮痛剤組成物
JP4102461B2 (ja) 解熱剤
JPS5835186A (ja) ジカルボキシアミノチアゾール誘導体およびそれを含有する免疫調節組成物
HK1018742B (en) Preparation containing a combination of 5-methylisoxazole-4-carboxylic acid-(4-trifluoromethyl)-anilide and n-(4-trifluoromethylphenyl)2-cyano-3-hydroxycrotonic acid amide
GB2201591A (en) Analgesic antipyretic and anti-inflammatory compositions
JPH05229944A (ja) モノアミノオキシダーゼｂ阻害因子
WO2000030645A1 (fr) Agent de prophylaxie et de traitement du trouble panique
EA042299B1 (ru) Фармацевтические композиции и их применения
JPS6144818A (ja) 抗動脈硬化症剤
JPS60218317A (ja) 抗てんかん薬
DE2456172B2 (de) Arzneimittel bei rheumatischen erkrankungen

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20170307